This website is about the chemotherapy medication pemetrexed.
It is also called LY231514.
Pemetrexed is a drug that belongs to a class of chemotherapeutic
drugs known as folate antimetabolites. Also known by the brand
name Alimta, the drug was approved by the United States Food and
Drug administration in February 2004 for the treatment of malignant
pleural mesothelioma (MPM) in combination with cisplatin, a platinum-containing
chemotherapeutic drug. Then in July 2004, the drug was approved
by the FDA as a second line agent for the treatment of advanced
or metastatic non-small cell lung cancer (NSCLC). Currently, the
drug is used as a single agent or in combination with other chemotherapeutic
agents for the treatment of other types of cancer such as breast
cancer, bladder cancer, colorectal cacinoma and cervical cancer.
It is developed and marketed by Eli Lilly and Company, an Indianapolis
What is this drug?
Material about how pemetrexed works in
Research into pemetrexed
Pemetrexed is an antifolate, a substance that blocks the activity
of folic acid. Also called folate antagonist.
Methotrexate (formerly known as amethopterin), is an earlier
antimetabolite drug used in treatment of cancer and autoimmune
diseases. It acts by inhibiting the metabolism of folic acid.
Methotrexate was developed in the late 1940 sand started in use
in the 1950s and is considered one of the early chemotherapy drugs.
Pemetrexed is used in treatment of some form of lung cancer and
in treatment of mesothelioma.
If you are interested in pemetrexed
for mesothelioma, click
This drug is used in treatment of mesothelioma.
This site was not prepared by medical professionals. Consult
a doctor for specific questions about treatment.